Lancet Gastroenterology & Hepatology最新文献

{"title":"Appendicectomy: a novel treatment for ulcerative colitis?","authors":"Offir Ukashi, Shomron Ben-Horin","doi":"10.1016/s2468-1253(25)00065-2","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00065-2","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"60 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial","authors":"","doi":"10.1016/s2468-1253(25)00026-3","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00026-3","url":null,"abstract":"<h3>Background</h3>The appendix might have an immunomodulatory role in ulcerative colitis. Appendicectomy has been suggested as a potentially therapeutic intervention to maintain remission in ulcerative colitis. We aimed to evaluate the clinical effectiveness of laparoscopic appendicectomy in maintaining remission in patients with ulcerative colitis.<h3>Methods</h3>We did a pragmatic, open-label, international, randomised controlled superiority trial in 22 centres across the Netherlands, Ireland, and the UK. Patients with established ulcerative colitis who were in remission but had been treated for disease relapse within the preceding 12 months were randomly assigned (1:1) to undergo appendicectomy plus continued maintenance medical therapy (intervention group) or to continue maintenance medical therapy alone (control group). Randomisation was done with a central, computer-generated allocation concealment, stratified by disease extent. Patients and treating physicians were unmasked to group allocation. The prespecified primary outcome was the proportion of patients with a disease relapse within 1 year, predefined as a total Mayo score of 5 or higher with an endoscopic subscore of 2 or 3, or, in absence of endoscopy, based on a centrally independent masked review by a critical event committee as an exacerbation of abdominal symptoms (eg, elevated stool frequency subscore of ≥1 point from baseline) with a rectal bleeding subscore of ≥1 or faecal calprotectin level above 150 μg/g or necessitating treatment intensification other than mesalazine. Analyses were done on an intention-to-treat principle. This trial is complete and was registered with the Netherlands Trial Register (NTR2883) and ISRCTN (ISRCTN60945764).<h3>Findings</h3>Between Sept 20, 2012, and Sept 21, 2022, 1386 patients were screened. 201 patients were randomly assigned to the appendicectomy group (n=101) or the control group (n=100). After exclusion of four patients due to eligibility violations (three had active disease and one received biological agents at time of randomisation), 99 patients in the appendicectomy group and 98 patients in the control group were included in the intention-to-treat analyses. The 1-year relapse rate was significantly lower in the appendicectomy group than in the control group (36 [36%] of 99 patients <em>vs</em> 55 [56%] of 98 patients; relative risk 0·65 [95% CI 0·47–0·89]; p=0·005; adjusted p=0·002). Adverse events occurred in 11 (11%) of 96 patients in the appendicectomy group and 10 (10%) of 101 patients in the control group. The most frequently reported adverse events were postoperative temporary self-limiting abdominal pain in the appendicectomy group (three [3%] patients) and skin rash in the control group (three [3%] patients). Two cases (2%) of low-grade appendiceal mucinous neoplasm were incidentally found in resected appendix specimens in the appendicectomy group. Serious adverse events occurred in two (2%) of 96 patients who underwent appendi","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"75 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retina and liver fibrosis screening for patients with type 2 diabetes","authors":"Yun-Chu Chen, Chun-Jen Liu, Tung-Hung Su","doi":"10.1016/s2468-1253(25)00092-5","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00092-5","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"37 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early-onset colorectal cancer: Hollyoaks tackles taboos and raises awareness","authors":"Joe Moody","doi":"10.1016/s2468-1253(25)00107-4","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00107-4","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"39 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retina and liver fibrosis screening for patients with type 2 diabetes – Authors' reply","authors":"Andrea Lindfors, Rickard Strandberg, Hannes Hagström","doi":"10.1016/s2468-1253(25)00096-2","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00096-2","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"246 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiome testing in clinical practice","authors":"Arshdeep Singh, Arshia Bhardwaj, Vandana Midha, Ajit Sood","doi":"10.1016/s2468-1253(24)00432-1","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00432-1","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"16 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Children's eating disorder services in England: at crisis point","authors":"","doi":"10.1016/s2468-1253(25)00104-9","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00104-9","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"37 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypovolaemic phlebotomy for hepatic resection","authors":"Alexandre Joosten, Sean Coeckelenbergh, Laurence Weinberg, Bernd Saugel","doi":"10.1016/s2468-1253(25)00001-9","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00001-9","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"23 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypovolaemic phlebotomy for hepatic resection – Authors' reply","authors":"Guillaume Martel, François M Carrier, Dean A Fergusson","doi":"10.1016/s2468-1253(25)00099-8","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00099-8","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"75 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ECCO'25","authors":"Bethany Gomersall","doi":"10.1016/s2468-1253(25)00106-2","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00106-2","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Duvakitug in Crohn's disease and ulcerative colitis</h2>Duvakitug—an anti-TL1A antibody—was safe and efficacious for induction in patients with Crohn's disease and in those with ulcerative colitis, according to data from the double-blind, phase 2b RELIEVE UCCD basket trial. In the first presentation by Vipul Jairath (London, ON, Canada), 138 adults with moderately to severely active Crohn's disease with inadequate response, loss of response, or intolerance to conventional or advanced therapies, or both, were randomly assigned (1:1:1) to</section></section><section><section><h2>Lusvertikimab for ulcerative colitis</h2>According to the phase 2 CoTikiS study presented by Arnaud Bourreille (Nantes, France), lusvertikimab—a first-in-class IL-7Rα antagonist—was safe and efficacious in patients with moderately to severely active ulcerative colitis and inadequate response to conventional therapies or failure of advanced therapies, or both. 136 participants were randomly assigned (1:1:1) to receive lusvertikimab 450 mg (n=36), lusvertikimab 850 mg (n=51), or placebo (n=49), intravenously, at weeks 0, 2, and 6. The</section></section><section><section><h2>Low-emulsifier diet for Crohn's disease</h2>Presented by Aaron Bancil (London, UK), the randomised, double-blind ADDapt trial found that a low-emulsifier diet was safe and efficacious in reducing disease activity in patients with mild to moderately active Crohn's disease. 154 patients with a Crohn's Disease Activity Index (CDAI) of 150–200 and evidence of inflammation (per faecal calprotectin ≥150 μg/g or endoscopy or radiology) were randomly assigned to receive a low-emulsifier diet (intervention; n=79) or the low-emulsifier diet plus</section></section>","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"25 1","pages":""},"PeriodicalIF":35.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}